Prostate Cancer Blog

/Prostate Cancer Blog/

Is Cyberknife a good prostate cancer treatment?

https://youtu.be/JnnE7X4tRZc Precision Radiation Treatment . Cyberknife has improved prostate cancer treatment as dynamically as robotic surgery . But, Cyberknife is not for everyone. See if it's right for you. Seth Blacksburg, MD and Darryl Mitteldorf, LCSW, explain. 1. How does radiation therapy actually work? 00:44 2. Does radiation therapy cause second cancers? 06:28 3. [...]

By |2018-07-18T12:43:54+00:00July 18th, 2018|Advanced Prostate Cancer|0 Comments

Emotional Crisis Resources From Malecare

Malecare's collection of emotion crisis resources.  Call these, even if you don't know if you "really" need them. Many international calls are free or affordable with SKYPE and many other apps. Feel OK about calling resources outside of your country. US: Hopeline (Suicide Prevention): 1-800-SUICIDE (1-800-784-2433) US: Suicide Hotline: 1-800-273-Talk (1-800-8255) UK: Samaritans (Nat’l [...]

By |2018-06-08T09:07:40+00:00June 8th, 2018|Advanced Prostate Cancer|0 Comments

Prostate Cancer And Agent Orange Is Not The Only Military Concern

Agent Orange is usually the first thing veterans with prostate cancer ask about.   Indeed, way back in 1998, Malecare was an early advocate for men exposed to Agent Orange. Military veterans as well as Vietnamese, Cambodian and Laotian civilians were exposed to Agent Orange, and many of those who are men are now diagnosed, [...]

By |2018-05-27T23:55:25+00:00May 25th, 2018|Advanced Prostate Cancer, Advocacy, Research|3 Comments

Erleada- New Treatment for Non-Metastatic Castrate Resistant Prostate Cancer

Erleada (apalutamide) has just received FDA approval as a drug for treating men with non-metastatic castration-resistant prostate cancer.   The proper pronunciation is Er ( Errr), (Like Her without the h) ) (lee) (long E) da. Now, repeat after me, "Erleada!" It's a pill that you take - I believe - four times a [...]

Apalutamide Looking Good as Treatment for Non-Metastatic Castrate Resistant Prostate Cancer

Non-Metastatic Castrate Resistant Prostate Cancer (nmCRPC)  usually leads to metastatic prostate cancer and death. There are no approved treatments for nmCRPC. Apalutamide is a taken-by-mouth androgen receptor inhibitor with antitumor activity in CRPC. There's a much talked and written about clinical trial called, SPARTAN, that investigated how well Apalutamide works on maintaining metastasis-free survival (MFS) [...]

XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces developing metastases or death

Non-metastatic Castrate Resistant prostate cancer patients take note.  The Phase 3 PROSPER trial in patients with non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC) showed that the use of XTANDI® (enzalutamide) plus androgen deprivation therapy (ADT) significantly reduced the risk of developing metastases or death by 71 percent compared to ADT alone.  It will be a [...]

Metastatic Prostate Cancer – Bone Metastases Might Be Controled With Xofigo For Two or More Years

Metastatic Prostate Cancer suffers have good news.  Xofigo, also known as Radium-223 (Ra-223), is a treatment for patients with castration-resistant prostate cancer (CRPC) and symptomatic (you can feel them) bone metastases (mets).  Early results of an international, open-label, phase 1/2 study (NCT01934790) showed that re-treating pts with Ra-223 was well tolerated with favorable effects on [...]

By |2018-02-06T11:09:18+00:00February 5th, 2018|Advanced Prostate Cancer, Hormone Therapy|0 Comments